Top Biomarkers for Assessing Metabolic Health
Top Biomarkers for Metabolic Health
What Leadership Teams Should Actually Be Measuring
A leader can walk out of their annual corporate health check with a clean bill of health while their metabolic function has been declining for years. The screening says healthy. The biology says otherwise. Here is what standard screening misses, and what a leadership team should actually be measuring.
A leader can walk out of their annual corporate health check with a clean bill of health while their metabolic function has been declining for years. Fasting glucose of 99 mg/dL: normal. Total cholesterol of 199 mg/dL: desirable. TSH of 4.0: within range. Meanwhile insulin resistance is building, visceral fat is accumulating, cardiovascular risk is climbing, and the brain's glucose delivery is quietly deteriorating. The screening says healthy. The biology says otherwise.
This is not a rare case. It is what standard corporate health screening is designed to do: detect established disease, not the years-long metabolic drift that precedes it.
Consider fasting insulin. A leader with a fasting insulin of 12 mIU/L sits comfortably inside most labs' reference range. But their HOMA-IR, a calculation combining fasting insulin and fasting glucose, may already indicate emerging insulin resistance. Nothing about this shows up as a diagnosis. It shows up as more pronounced post-lunch crashes, visceral fat that won't respond to diet changes, and a cardiovascular risk clock that has quietly started running. None of it appears on a standard screening. All of it affects the person's capacity to lead.
The "Medicine 3.0" framework in modern preventive medicine is built on exactly this principle: the interventions that matter most are the ones that catch subclinical trajectories years before they become diagnoses. Applied to leadership health, that means the biomarkers worth measuring are not the ones that detect disease, but the ones that detect the metabolic shifts already degrading cognitive function, physical resilience, and stress tolerance, long before anything is technically wrong.
The Insulin-Glucose Axis: The Variable That Matters Most
Insulin resistance is the slow, largely invisible process by which cells stop responding efficiently to insulin's signal to absorb glucose. The pancreas compensates by producing more insulin, and blood sugar can stay "normal" for five to ten years while this compensatory mechanism works overtime. By the time fasting glucose or HbA1c actually cross into abnormal territory, insulin resistance has usually been present for years.
The biomarker that catches this earlier is fasting insulin, combined with the HOMA-IR calculation: (fasting insulin × fasting glucose) ÷ 405.
This is not a purely academic distinction. Chronically elevated insulin drives visceral fat accumulation, promotes inflammatory signalling, accelerates atherosclerosis, disrupts sex hormone balance, and, directly relevant to leadership performance, impairs the brain's glucose utilisation. The prefrontal cortex, which handles the executive functions leadership actually consists of, is unusually dependent on efficient glucose delivery. Insulin resistance blunts that delivery years before it becomes a diagnosis.
ApoB: The Cardiovascular Marker Standard Panels Leave Out
Apolipoprotein B (ApoB) is the protein that coats every atherogenic lipoprotein particle, LDL, VLDL, IDL, and Lp(a), with exactly one ApoB molecule per particle. That makes ApoB a direct particle count, and particle count, not cholesterol concentration, is what actually predicts cardiovascular events. Two people can have identical LDL cholesterol readings and very different cardiovascular risk, because one is carrying more, smaller LDL particles than the other. Standard LDL-C testing cannot see this difference. ApoB can.
The clinical consensus has shifted decisively toward ApoB: the 2023 European Atherosclerosis Society statement formally endorsed it as the primary lipid risk marker, and the March 2026 AHA/ACC dyslipidaemia guidelines followed with a recommendation to measure it in at-risk adults. Leading preventive-medicine clinicians advocate a target below 60 mg/dL, considerably more aggressive than standard "desirable" thresholds. Despite this, fewer than 1% of the insured population gets ApoB tested in a given year, and the figure in India is likely lower still.
Lp(a) and hs-CRP: The Genetic and Inflammatory Markers Nobody Tests For
Lp(a): the genetic risk factor nobody tests for
Lipoprotein(a), or Lp(a), is structurally similar to LDL but carries an additional protein that makes it more pro-thrombotic and pro-atherogenic. It is roughly 90% genetically determined, largely unmoved by lifestyle change, and not included in standard lipid panels, tested in fewer than 1% of people annually despite affecting a substantial share of the population at levels that meaningfully raise cardiovascular risk. South Asian populations tend to run higher.
The practical value of testing it is straightforward: because Lp(a) is genetically stable, it only needs measuring once. An elevated result changes the entire risk-management strategy, a lower ApoB target, more frequent imaging, earlier consideration of pharmacological intervention, even when every other marker looks unremarkable.
hs-CRP: the number that reveals cumulative inflammatory load
High-sensitivity C-reactive protein (hs-CRP) measures the low-grade, chronic inflammation that drives atherosclerosis, insulin resistance, and cognitive decline, distinct from the acute inflammation a standard CRP test picks up after infection or injury.
Chronic inflammation is the connective tissue running through metabolic syndrome, cardiovascular disease, and cognitive decline, and it is driven by a specific, largely modifiable set of factors: visceral fat (which is metabolically active and secretes inflammatory cytokines), inadequate sleep (inflammatory markers rise within two to three nights of restriction), chronic psychological stress, gut dysbiosis, and a diet heavy in ultra-processed food and refined sugar. For a leadership population, hs-CRP is arguably the single best available marker of how much cumulative inflammatory cost their lifestyle is generating, and none of it appears on a standard screening panel.
The Complete Panel: What Leadership Teams Should Actually Be Measuring
A meaningful metabolic assessment for a leadership population goes well beyond fasting glucose and a basic lipid panel.
Glycaemic and insulin markers. Fasting glucose, fasting insulin, HOMA-IR, HbA1c, and ideally a period of continuous glucose monitoring to capture real-world variability.
Lipid and cardiovascular markers. A standard lipid panel plus ApoB, Lp(a) measured once, and the triglyceride-to-HDL ratio as an insulin resistance proxy.
Inflammatory markers. hs-CRP, homocysteine, and the omega-3 index.
A full thyroid panel. TSH, free T3, free T4, and thyroid antibodies, not TSH alone.
Micronutrient status. Ferritin, vitamin D, B12, and RBC magnesium.
Body composition, fitness, and resilience. Body composition via DEXA rather than BMI, cardiovascular fitness via VO2 max, and resting HRV tracked longitudinally as a marker of autonomic resilience.
The thyroid panel deserves particular emphasis. Standard screenings measure TSH alone, which can miss subclinical hypothyroidism (normal TSH with low-normal free T3/T4) and autoimmune thyroiditis entirely. Thyroid dysfunction is markedly more common in women than men, and the fatigue, cognitive fog, and mood disturbance it produces are routinely misattributed to stress or ageing rather than investigated as what they are.
Why a single lipid panel can already tell you more
Not every organisation is ready to commission a full biomarker programme immediately. For leadership teams where fasting insulin testing isn't yet available, the triglyceride-to-HDL ratio, calculable from a standard lipid panel most companies already run, serves as a useful proxy for insulin resistance. Below 1.0 suggests good insulin sensitivity; 1.0 to 2.0 suggests emerging resistance; above 2.0 suggests significant resistance and metabolic syndrome risk.
This matters practically: a CHRO who cannot immediately fund comprehensive testing for an entire leadership team can, at essentially no additional cost, calculate this ratio from data the organisation is already paying to collect, and use it to identify who would benefit most from a fuller assessment.
Homocysteine and the vegetarian blind spot
Homocysteine is a sensitive, inexpensive, and widely available marker that rises when B-vitamin status, specifically folate, B12, and B6, is inadequate, and independently predicts cardiovascular and cognitive risk when chronically elevated. For Indian leadership populations, this marker carries particular weight: B12 is found almost exclusively in animal products, and vegetarian diets, common across Indian corporate culture for cultural and religious reasons as much as personal choice, carry meaningfully elevated risk of functional B12 insufficiency. Homocysteine rises before B12 itself drops below standard reference thresholds, making it an earlier warning signal, and one that is cheap enough to include in any Indian executive health programme with no meaningful cost barrier.
What blood data alone cannot tell you
Blood biomarkers are a snapshot. Wearable data, HRV, sleep architecture, activity, and continuous glucose data, supplies the trajectory and the context that explains why the snapshot looks the way it does. An executive whose hs-CRP climbs over six months means little on its own. Overlaid with wearable data showing a parallel decline in sleep duration, a drop in HRV, and a near-total stop in exercise, the picture becomes causally clear, and the intervention becomes specific rather than generic.
What South Asian Populations Need Adjusted
Applying Western reference ranges to Indian biomarker data understates risk. BMI and waist circumference thresholds for metabolic risk sit meaningfully lower in South Asian populations than in European ones. An Indian executive with a BMI of 23 can carry the metabolic risk profile of a European executive several BMI points higher, a pattern explained by ectopic fat deposition occurring at lower body weights in this population.
Lp(a) tends to run higher. Cardiovascular events occur roughly a decade earlier. An Indian executive whose lipid panel and BMI both look unremarkable by Western standards may already be carrying central obesity and significant insulin resistance by South Asian-adjusted standards.
Building This Into an Organisational Programme
For CHROs and People leaders considering this at the leadership-team level, a few design principles determine whether the programme actually works. Start with the C-suite and senior leadership, a smaller, higher-impact population, before scaling wider. Run a comprehensive panel at baseline and repeat every six months, since a single measurement is a snapshot with no trajectory information attached. Keep individual results strictly confidential to the participant; the organisation should only ever see aggregated, anonymised population data, because leaders will not engage honestly with a programme that shares their personal health data with their employer. And pair every result with a qualified practitioner who can interpret it in context, since biomarker data without clinical interpretation is noise, not insight.
The cost case is not subtle either. A comprehensive assessment for one executive runs a small fraction of what replacing a single C-suite leader costs in recruitment alone, before accounting for lost institutional knowledge or the cost of a cardiac event in a senior leader mid-tenure. The programme cost is a rounding error next to the cost of the events it is designed to catch early.
What ages and sexes need different panels
A single biomarker panel run identically across a 32-year-old and a 52-year-old, or across male and female leaders, is biologically illiterate. Priorities shift with age: in the 30s, the focus is establishing a clean baseline and catching early insulin resistance; in the 40s, cardiovascular markers, ApoB, Lp(a), and increasingly coronary artery calcium scoring, move to the centre, alongside hormonal assessment for women approaching perimenopause; in the 50s, cognitive-relevant markers like homocysteine, B12, and the omega-3 index, plus bone density, become more relevant.
Sex-specific interpretation matters just as much. Ferritin in menstruating women frequently sits in a range standard labs call "normal" but which is associated with real fatigue, cognitive impairment, and exercise intolerance; optimal ferritin for women runs meaningfully higher than the bottom of most reference ranges. Thyroid disorders affect women several times more often than men, and the perimenopausal transition, which can begin well before menopause itself, produces thyroid and hormonal shifts that a TSH-only test simply will not catch. A leadership health programme that runs the identical panel for every participant regardless of sex is missing exactly the markers most likely to explain unexplained fatigue and cognitive variability in its female leaders.
What Doesn't Work
A few common approaches are worth naming as ineffective, because they are also the most common.
The Minimal Annual Screening
Annual screenings using only fasting glucose, total cholesterol, and TSH miss the majority of subclinical dysfunction by design. Without fasting insulin, ApoB, hs-CRP, a full thyroid panel, and micronutrient testing, the screening simply cannot see the problem developing.
A Single Measurement, No Follow-Up
A single measurement without any follow-up is an expensive snapshot, not a health strategy. The value in biomarker testing sits almost entirely in tracking whether a number is moving in the right direction, which requires at least two data points.
Treating BMI as Body Composition
A muscular executive at a higher BMI can be metabolically healthier than a sedentary one at a lower BMI carrying more visceral fat. DEXA scanning provides the resolution BMI simply cannot.
Equally, supplementing anything, vitamin D, iron, magnesium, without first testing baseline levels risks both under- and over-correction, and treating an elevated marker like triglycerides in isolation, without addressing the insulin resistance usually driving it, fixes the number without touching the mechanism producing it.
Common Questions on Biomarkers and Metabolic Health
What is HOMA-IR and what counts as a healthy range?
HOMA-IR is calculated as (fasting insulin × fasting glucose) ÷ 405, and it estimates how resistant the body's cells have become to insulin's signal. A result below 1.0 indicates strong insulin sensitivity, 1.0 to 1.9 signals early resistance, 2.0 to 2.9 is significant resistance, and above 3.0 approaches pre-diabetic metabolism. Most standard corporate health panels don't measure fasting insulin at all, so they cannot calculate HOMA-IR and miss this early warning stage entirely.
Is ApoB a better test than LDL cholesterol?
For cardiovascular risk, yes. ApoB counts the actual number of atherogenic particles in the blood, LDL, VLDL, IDL, and Lp(a), one ApoB molecule per particle. Particle count, not cholesterol concentration, is what predicts cardiovascular events. Two people can have identical LDL cholesterol but very different ApoB counts and very different risk. The 2023 European Atherosclerosis Society statement and the March 2026 AHA/ACC dyslipidaemia guidelines both recommend measuring it in at-risk adults, yet fewer than 1% of the insured population gets tested in a given year.
What does Lp(a) tell you that a standard lipid panel does not?
Lp(a) is a genetic cardiovascular risk factor, roughly 90% inherited and largely unmoved by diet or exercise, that is not included in standard lipid panels and is tested in fewer than 1% of people annually. South Asian populations tend to run higher. Because it is genetically stable, it only needs testing once, and an elevated result changes the entire risk-management strategy, a lower ApoB target, more frequent imaging, earlier consideration of medication, even when every other marker looks normal.
What does hs-CRP measure and what level is considered optimal?
High-sensitivity C-reactive protein (hs-CRP) measures low-grade, chronic inflammation, distinct from the acute inflammation a standard CRP test detects after infection or injury. Below 1.0 mg/L is optimal, 1.0 to 3.0 mg/L signals moderate risk and underlying inflammatory load, and above 3.0 mg/L, absent acute infection, warrants investigation. It is driven by visceral fat, poor sleep, chronic stress, gut dysbiosis, and a diet heavy in ultra-processed food, making it one of the best single markers of cumulative lifestyle cost.
Why do South Asian executives need different biomarker thresholds?
Applying Western reference ranges to Indian biomarker data understates risk. BMI and waist circumference thresholds for metabolic risk sit meaningfully lower in South Asian populations, because ectopic fat builds up at lower body weights. Lp(a) tends to run higher, and cardiovascular events occur roughly a decade earlier than in Western populations. An executive whose BMI and lipid panel look unremarkable by Western standards may already be carrying significant insulin resistance by South Asian-adjusted standards, which is why ApoB and fasting insulin should be standard, not optional, additions to any Indian executive health panel.
Organisational Health and Performance Programme
Your leadership team's health checks might be giving them a false sense of security. Is your programme measuring what actually matters?
Our Organisational Health and Performance Programme builds comprehensive, confidential biomarker assessments for leadership teams, calibrated for South Asian thresholds and tracked over time, so every intervention is targeted rather than generic.
Explore Organisational ProgrammesResearch References
European Atherosclerosis Society Consensus Statement (2023) - Referenced for the formal endorsement of ApoB as the primary lipid risk marker over LDL cholesterol.
AHA/ACC Dyslipidaemia Guidelines (March 2026) - Referenced for the recommendation to measure ApoB in at-risk adults.
Disclaimer
The information presented in this article is intended for leadership teams and human resources professionals evaluating executive health programmes. It is not medical advice, and no biomarker result should be interpreted or acted on without a qualified healthcare practitioner. Reference ranges and clinical guidelines referenced here reflect the current state of published research, which continues to evolve. Deep-Health does not endorse any specific diagnostic test, laboratory, or commercial programme without prior assessment. This content reflects the author's analysis based on published research and professional experience.
Sanjay Dev
Founder of Deep-Health. 20-plus years working with founders, executives, athletes, and organisations at the intersection of neuroscience, physiology, and behavioural biochemistry.
View all articles by Sanjay